fusidic acid has been researched along with amikacin in 13 studies
| Studies (fusidic acid) | Trials (fusidic acid) | Recent Studies (post-2010) (fusidic acid) | Studies (amikacin) | Trials (amikacin) | Recent Studies (post-2010) (amikacin) |
|---|---|---|---|---|---|
| 1,742 | 117 | 344 | 4,739 | 485 | 1,316 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Beceiro, A; Bou, G; Canle, D; Fernández, A; Lasa, I; Latasa, C; Mallo, S; Molina, F; Pérez, A; Pérez, S; Poza, M; Tomás, Mdel M; Villanueva, R | 1 |
| Amblard, M; Bastide, L; Gualtieri, M; Leonetti, JP; Martinez, J; Pugniere, M; Roquet, F; Villain-Guillot, P | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ashenden, S; Bender, A; Cokol, M; Karakoc, I; Kuru, N; Mason, DJ; Meral, S; Stott, I; Weinstein, ZB | 1 |
| Durgham, SM; Ishag, AJ; Shibl, AM | 1 |
| Bonner, DP; Fung-Tomc, J; Kolek, B | 1 |
| Barbiery, P; Courcol, RJ; Roussel-Delvallez, M; Wallet, F | 1 |
| Ansorg, R; Fabry, W; Schmid, EN | 1 |
| Dudzevicius, V; Sakalauskas, R; Vitkauskiene, A | 1 |
| Appelbaum, PC; Beachel, L; Clark, C; Credito, K; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
13 other study(ies) available for fusidic acid and amikacin
| Article | Year |
|---|---|
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
Topics: Bacterial Proteins; Base Sequence; beta-Lactamases; Carrier Proteins; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Genes, MDR; Genetic Vectors; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Porins | 2007 |
Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms.
Topics: Animals; Anti-Bacterial Agents; Biofilms; CHO Cells; Cricetinae; Cricetulus; DNA-Directed RNA Polymerases; Furans; Gram-Positive Bacteria; Microbial Sensitivity Tests; Rhodanine; Staphylococcus epidermidis; Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure.
Topics: Anti-Bacterial Agents; Drug Interactions; Molecular Structure | 2017 |
In vitro susceptibility of methicillin-resistant Staphylococcus aureus to imipenem and other antimicrobial agents.
Topics: Amikacin; Anti-Bacterial Agents; Cefepime; Cephalosporins; Clindamycin; Fusidic Acid; Imipenem; Methicillin; Microbial Sensitivity Tests; Norfloxacin; Pefloxacin; Penicillin Resistance; Rifampin; Staphylococcus aureus; Thienamycins; Tobramycin; Vancomycin | 1987 |
Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.
Topics: Amikacin; Cefepime; Cephalosporins; Ciprofloxacin; Drug Resistance, Microbial; Fusidic Acid; Gentamicins; Imipenem; Methicillin Resistance; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Staphylococcus aureus | 1993 |
Effect of vancomycin and teicoplanin alone or in combination with fusidic acid or amikacin against methicillin-resistant staphylococci.
Topics: Amikacin; Anti-Bacterial Agents; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fusidic Acid; Logistic Models; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus; Teicoplanin; Vancomycin | 1997 |
Comparison of the E test and a proportion dilution method for susceptibility testing of Mycobacterium tuberculosis.
Topics: Amikacin; Antitubercular Agents; Ciprofloxacin; Clarithromycin; Fleroxacin; Fusidic Acid; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Streptomycin | 1995 |
[The impact of antibiotic use on hospital-acquired pneumonia: data of etiology tests].
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bronchoalveolar Lavage Fluid; Ceftazidime; Cefuroxime; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fusidic Acid; Gentamicins; Haemophilus Infections; Haemophilus influenzae; Humans; Male; Methicillin; Microbial Sensitivity Tests; Middle Aged; Penicillins; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Staphylococcus aureus; Sulbactam; Vancomycin Resistance | 2003 |
In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.
Topics: Amikacin; Burkholderia cepacia; Cystic Fibrosis; Drug Synergism; Fusidic Acid; Humans; Pseudomonas aeruginosa; Staphylococcus aureus; Tobramycin | 2011 |